24th European Hematology Association (EHA) Annual Congress  
13-16 June 2019 – Amsterdam (The Netherlands)  

MYELOMA AGENDA  

THURSDAY, 13th June  

- **Celgene - Discovery of therapeutic synergies leveraging the immune system against multiple myeloma**  
  Room: Auditorium  
  Time: 10:15 - 11:45  
  Type: Satellite Symposium  
  Chair: Jesús San Miguel, Clinical University Navarra, Pamplona, Spain  
  - The quest for synergy: combination strategies in MM – J. San Miguel  
  - The journey towards deeper responses and improved outcomes in NDMM – T. Fancon  
  - Mapping treatment strategies for early-relapse patients – X. Leleu  
  - Guiding the immune system to address unmet needs in RRMM – N. Rage

- **Amgen - Rebooting the myeloma treatment programme**  
  Room: Elicium 2  
  Time: 12:30 - 14:00  
  Type: Satellite Symposium  
  Chair: Jesús San Miguel, Clinical University Navarra, Pamplona, Spain  
  - Foreword: Steady stream and changing seas in myeloma – J. San Miguel  
  - An uphill battle: Overcoming treatment resistance – K. Weisel  
  - A delicate balance: Tailoring treatment for elderly patients – X. Leleu  
  - Big Changes May Arise: Evolution of immunotherapies – H. Einsele

- **Sanofi Genzyme - Management of relapsed and refractory multiple myeloma with novel monoclonal antibody-based regimens: an interactive conversation with the experts**  
  Room: Forum Hall  
  Time: 14:45 - 16:15  
  Type: Satellite Symposium  
  Chair: M. Attal, Toulouse University Institute of Cancer – Oncopole, France  
  - Introduction and Voting on FAQs – M. Attal  
  - Available Agents and Treatment Sequencing in Relapsed/Refractory Multiple Myeloma – K. Young  
  - Clinical Perspective – K. Weisel
- **Medscape Oncology - Real world treatment of R/R myeloma: clinical trials vs clinical practice**
  Room: Hall 3A
  Time: 14:45 - 16:15
  Type: Satellite Symposium
  Chair: G. Jackson, Newcastle Hospitals NHS Foundation Trust, United Kingdom
  - Welcome and Introductions – G. Jackson
  - Clinical Trials Inform - But do not Reflect Clinical Practice – M. Boccadoro
  - Clinical Trials vs Clinical Practice: Why the Discrepancies? – A Chari
  - How can we achieve our Goals in the Real World? – panel

- **Medscape Oncology - Building a better foundation: targeting apoptosis to enhance outcomes in relapsed/refractory myeloma**
  Room: Auditorium
  Time: 17:00 - 18:30
  Type: Satellite Symposium
  Chair: S. Kumar, Mayo Clinic College of Medicine, Rochester, United States
  - What’s important in defining therapy choices? – T. Fancon
  - New Paradigms in Myeloma: Top Down - Targeting the Cell Surface – J. San Miguel
  - New Paradigms in Myeloma: Bottom Up - Targeting Cell Survival – S. Kumar
  - Challenging today’s paradigms: Where will new agents fit in practice? – G. Morgan

- **Oncopeptides - Challenging the treatment paradigm in multiple myeloma**
  Room: Hall 3B
  Time: 19:15 - 20:45
  Type: Satellite Symposium
  Chair: X. Leleu, CHU La Miletrie, Poitiers, France
  - Challenges in treating myeloma after 1st/2nd relapse in the year 2019 and onwards – M. Dimopoulos
  - Tolerability aspects on treating myeloma – F. Davies
  - Next generation of targeted drugs for RRMM – P. Richardson
FRIDAY, 14th JUNE

- **Resistance mechanisms to novel anti-MM agents**
  Room: Hall E-106
  Time:
  Type: Science-in-focus
  Chair: N Weinhold, University Hospital Heidelberg, Germany
  - Resistance to IMiDs in MM: Is Cereblon the whole story? – E Ocio
  - Inside the gearbox of proteasome inhibitor-refractory multiple myeloma – C Driessen
  - Resistance to immunotherapeutic agents in multiple myeloma – T Mutis

- **Optimal sequencing in relapsed/refractory myeloma**
  Room: Emerald
  Time: 11:30 – 12:30
  Type: Meet-the-expert
  Speaker: F. Gay

- **Myeloma and other monoclonal gammopathies - Biology & Translational Research**
  Room: Poster area
  Time: 17:30 – 19:00
  Type: Poster session
SATURDAY, 15th JUNE

- **Multiple myeloma: Novel outcome endpoints in trials and in daily practice**
  Room: Hall 3A
  Time: 08:30 - 09:30
  Type: Scientific Working group
  Chair: M. Delforge
  - Is MRD the new predictor for survival? – S. Oliva
  - Assessment of serial treatments in myeloma – E. Terpos
  - Should PROMs be a standard part of outcome measurements? – H Ludwig

- **Multiple myeloma**
  Room: Auditorium
  Time: 09:45 - 11:15
  Type: Educational Session
  Chair: S. Zweegman
  - The bone marrow niche in plasma cell disorders – I. Ghobrial
  - MRD in myeloma: Prognostic and therapeutic implications (including imaging) – RG. Owen
  - Front-line treatment of multiple myeloma – M. Cavo

- **Immunotherapy in relapsed/refractory multiple myeloma**
  Room: Auditorium
  Time: 11:30-12:45
  Type: Oral Session
  Chairs: A. Larocca and E. Ocio
  - (S823) Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus Intravenous (IV) Daratumumab (Dara) administration In patients with relapsed Or Refractory Multiple Myeloma: Columba
  - (S824) A phase 3 randomized, open-label, multicenter study of isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma (RRMM)
  - (S825) Evaluation of Amg 420, an anti-BCMA bispecific t-cell engager (bite & #174; ) immunotherapy, in r/r multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase 1 dose escalation study
  - (S826) Improved efficacy and safety of a dual-target CAR-T cell therapy targeting BCMA and CD38 for relapsed/refractory multiple myeloma from a phase I study
  - (S827) Clinical responses and pharmacokinetics of fully human BCMA targeting CAR-T cell therapy in relapsed/refractory multiple myeloma
• **EHA-EANM Joint Symposium: FDG PET/CT in Multiple Myeloma: a useful tool?**
  Room: Hall E102  
  Time: 14:45 - 15:45  
  Type: Joint Symposium  
  Chair: TBD  
  - The hematologist perspective – E Zamagni  
  - The nuclear medicine perspective – C. Nanni

• **Myeloma and other monoclonal gammopathies - Clinical**
  Room: Poster area  
  Time: 17:30 – 19:00  
  Type: Poster session
SUNDAY, 16th JUNE

- **Novel strategies in multiple myeloma**
  Room: Auditorium
  Time: 08:00 – 9:15
  Type: Oral session
  Chairs: S. Zweegman and F. Gay
  - (S1602) Carfilzomib and dexamethasone maintenance prolong time to progression following salvage ASTC in multiple myeloma: a randomized phase 2 trial by the nordic myeloma study group
  - (S1603) First clinical (phase 1b/2a) study of iberdomide (cc-220; IBER), a celmod, in combination with dexamethasone in patients with relapsed/refractory multiple myeloma
  - (S1604) Effectiveness of denosumab compared to zoledronic acid in bone disease treatment of multiple myeloma (MM): a meta-analysis
  - (S1605) Horizon (OP-106): updated efficacy and safety of melflufen in relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (DARA) and/or pomalidomide (POM)
  - (S1606) Safety and efficacy of combination of selinexor, daratumumab, and dexamethasone (SDD) in patients with multiple myeloma (MM) previously exposed to proteasome inhibitors and immunomodulatory drugs

- **Multiple myeloma**
  Room: Auditorium
  Time: 09:30 - 11:00
  Type: Educational Session
  Chair: S. Zweegman
  - The bone marrow niche in plasma cell disorders – I. Ghobrial
  - MRD in myeloma: Prognostic and therapeutic implications (including imaging) – RG. Owen
  - Front-line treatment of multiple myeloma – M. Cavo